Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11502744 
Wan KF, et al. (2001) The inhibitory gamma subunit of the type 6 retinal cyclic guanosine monophosphate phosphodiesterase is a novel intermediate regulating p42/p44 mitogen-activated protein kinase signaling in human embryonic kidney 293 cells. J Biol Chem 276, 37802-8 11502744
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
EGF GRK2 (human) augment treatment-induced increase
siRNA EGF PDE6G (human) inhibit treatment-induced increase
EGF PDE6G (human) augment treatment-induced increase
thrombin increase
siRNA thrombin PDE6G (human) inhibit treatment-induced increase
thrombin PDE6G (human) augment treatment-induced increase
thrombin GRK2 (human) augment treatment-induced increase

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
EGF GRK2 (human) augment treatment-induced increase
siRNA EGF PDE6G (human) inhibit treatment-induced increase
EGF PDE6G (human) augment treatment-induced increase
thrombin increase
siRNA thrombin PDE6G (human) inhibit treatment-induced increase
thrombin PDE6G (human) augment treatment-induced increase
thrombin GRK2 (human) augment treatment-induced increase

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
EGF GRK2 (human) augment treatment-induced increase
siRNA EGF PDE6G (human) inhibit treatment-induced increase
EGF PDE6G (human) augment treatment-induced increase
thrombin increase
siRNA thrombin PDE6G (human) inhibit treatment-induced increase
thrombin PDE6G (human) augment treatment-induced increase
thrombin GRK2 (human) augment treatment-induced increase

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
EGF GRK2 (human) augment treatment-induced increase
siRNA EGF PDE6G (human) inhibit treatment-induced increase
EGF PDE6G (human) augment treatment-induced increase
thrombin increase
siRNA thrombin PDE6G (human) inhibit treatment-induced increase
thrombin PDE6G (human) augment treatment-induced increase
thrombin GRK2 (human) augment treatment-induced increase

T62-p - PDE6G (mouse)
Orthologous residues
PDE6G (human): T62‑p, PDE6G (mouse): T62‑p, PDE6G (cow): T62‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GRK2 (mouse)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
thrombin increase
Downstream Regulation
 Effect of modification (function):  activity, induced, phosphorylation
 Comments:  increases ERK phosphorylation


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.